A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Pidilizumab (Primary)
- Indications Glioma
- Focus Adverse reactions
- 11 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2016 Preliminary data were presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO) 2016, according to a Medivation media release.
- 16 Jun 2016 Interim results (n=9) published in a Medivation media release.